Zydus today announced that the company has started the supplies of its COVID-19 vaccine ZyCoV-D, to the Government of India against their order from its newly commissioned state-of-the-art, Zydus Vaccine Technology Excellence Centre at the Zydus Biotech Park in Changodar, Ahmedabad. The group is also planning to make the vaccine available in the private market. ZyCoV-D is a three dose vaccine administered intradermally using the painless PharmaJet® needle free system, Tropis®, on day 0, day 28 and day 56.
The vaccine will be priced at Rs 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST.
Zydus VTEC manufactures the drug substance for the needle-free DNA Plasmid vaccine, ZyCoV-D. The manufacturing process and in process material transfers within the plant are automated.
Zydus has also entered into a definitive agreement with Shilpa Medicare Limited, a contract manufacturing organization to produce mutually agreeable doses of ZyCoV-D. The company also entered into an agreement with Enzychem Lifesciences of Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine.
Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 406.80 as compared to the previous close of Rs. 406.70. The total number of shares traded during the day was 90812 in over 3062 trades.
The stock hit an intraday high of Rs. 412.90 and intraday low of 405.05. The net turnover during the day was Rs. 37091199.00.